Enables GTPase activating protein binding activity and GTPase activator activity. Predicted to be involved in several processes, including axon development; establishment or maintenance of actin cytoskeleton polarity; and regulation of plasma membrane bounded cell projection organization. Predicted to act upstream of or within several processes, including negative regulation of Rho protein signal transduction; negative regulation of vascular permeability; and nervous system development. Predicted to be located in actin cytoskeleton; ciliary basal body; and cytoplasm. Predicted to be active in cytosol. Orthologous to human ARHGAP35 (Rho GTPase activating protein 35); PARTICIPATES IN ephrin - ephrin receptor bidirectional signaling axis; platelet-derived growth factor signaling pathway; INTERACTS WITH (+)-schisandrin B; 17alpha-ethynylestradiol; 17beta-estradiol.
[Clofibrate co-treated with Acetaminophen] affects the expression of ARHGAP35 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of ARHGAP35 mRNA]
AG 1879 inhibits the reaction [Folic Acid results in increased activity of ARHGAP35 protein] and ARHGAP35 protein affects the reaction [Folic Acid results in decreased activity of RHOA protein]
[Clofibrate co-treated with Acetaminophen] affects the expression of ARHGAP35 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of ARHGAP35 mRNA]
[perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of ARHGAP35 mRNA and [perfluorooctane sulfonic acid co-treated with Pectins] results in decreased expression of ARHGAP35 mRNA
[LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in increased expression of ARHGAP35 protein
Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution, and activity of p21ras GTPase-activating protein.
